Company intelligence / Profile preview

Motiva

Ownership: Private
Development stage: Commercial

Overview

Motiva Implants, developed by Establishment Labs, are next-generation breast implants featuring patented SmoothSilk®/SilkSurface® technology designed to reduce inflammation and complications such as capsular contracture. Clinical trials, including a four-year U.S. IDE study, have shown very low complication rates and high patient satisfaction compared to historical benchmarks[1][5][7]. The implants received FDA approval in September 2024 for use in the United States[5].

Therapeutic areas: OtherWomen's Health
Modalities: Device (breast implant)
Industry: Implantable Medical Devices

Partnerships

Not explicitly listed; clinical collaborations with leading plastic surgeons and research centers globally[1][7].

Beyond the preview

Go deeper on Motiva.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Motiva.

Explore the full profile